Indy Hematology Review

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

2024
2023
2022
2021
Indy Hematology Review 2019 Conference
Indy Hematology Review 2018 Conference
MPN Myeloma Leukemia Benign Hematology Lymphoma Challenging Case Presentations Blood Disorders Indy Hematology Review 2018 Nursing and Allied Providers Symposium Agenda 2018
Events

Playback speed

By Indy Hematology Review FEATURING Kenneth Anderson

June 24, 2019

Feat. J. Mccloskey

Indy Hematology Review 2019 Conference

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

Indy Hematology Review

A. Fleischman

Indy Hematology Review

A. Fleischman

Indy Hematology Review

H. Kantarjian

Indy Hematology Review

H. Kantarjian

Login

Login

Join VuMedi

Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the First MM Platform Trial - MyDRUG

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

New Approval for Frontline Consolidation in Patients with CD19-posit…

Review of Emerging Therapies and Top Trials in Hematologic Malignanc…

Therapy for Newly Diagnosed Myeloma - Role of Transplant and MRD, DA…

Novel Immune Therapies in Myeloma: BCMA Immunotoxin, Bites, and CAR …

Targeting Mutations in Myeloma with Venetoclax and Development of th…

Waldenström's Macroglobulinemia - Novel Therapeutic Approaches Targe…

Treating CLL in 2019: Chemoimmunotherapy is Superior to Chemotherapy…

CLL: Should Anyone Still be Treated with Chemoimmunotherapy, Improvi…

Treatment of Follicular Lymphoma and Other Indolent Lymphomas: Is Ta…

Hodgkin Lymphoma - Revolutionized Treatment Options Using Brentuxima…

Treatment and New Trials in DLBCL - Modifications to R-CHOP Based on…

Axi cell CAR T-cell Therapy for Refractory DLBCL - Overview of ZUMA-…

Brentuximab Vedotin for Previously Untreated Peripheral T-cell Lymph…

Immune Thrombocytopenic Purpura (ITP) - Immunopathogenesis, New ASH …

Pharmacological Landscape of the Direct Oral Anticoagulants - Overvi…

Follicular Lymphoma Chemo Treatment Regimens - Chemoimmunotherapy, R…

Chemo-free Regimens in Follicular Lymphoma

Starting Therapy in CML - Imatinib Treatment, Early Molecular Respon…

CML Treatment - Investigational Agents, Reducing Dosage to Reduce Si…

Acute Myeloid Leukemia - Overview of Available Novel Agents with Uni…

Risk Assessment and Genetic Mutations in MDS

Are There New Approaches in Lower Risk MDS? Overview of Lenalidomide…

Treatment of High Risk MDS: Azacitidine Trials, Immune Checkpoint In…

Allo HSCT: Improvements in Transplant Outcomes, Myeloablative Vs. Re…

Relapse After Allo HSCT - Treatment Strategies and Overview of Relat…

Hematopoietic Stem Cell Transplantation: Types of Transplant, Compli…

Art Therapy and Patients With Cancer: Healing Through Creativity

Severe Aplastic Anemia: Diagnosis & First Line and Refractory Diseas…

Paroxysmal Nocturnal Hemoglobinuria (PNH) - Biology, Pathogenesis, E…

Molecular Anatomy of MPNs, Scoring Systems & Prognostic Scoring in P…

Review of ASH MPN Therapies: Pegylated Interferon vs. Hydroxyurea & …

Improvements in Treating Ph-like ALL, Trials in Pre B-ALL & Blinatum…

Immuno-oncology in ALL - Salvage Standard of Care, Mini-HCVD Plus In…